MOVING SCIENCE FORWARD
MultiPark is a strategic research area funded by the Swedish Government. Building on the strong tradition of cutting-edge research on Parkinson's and Alzheimer's diseases at Lund University, our vision is to create new and innovative strategies for improved and novel treatments, disease modifications and eventually cures for neurodegenerative diseases, in order to improve the quality of life for people living and ageing with these disorders.
With a simple blood test, scientists hope to make an earlier distinction between Parkinson's and related diseases, so-called atypical parkinsonism. Today, such a diagnosis requires samples of spinal fluid, a more painful, invasive and expensive method. Researchers at Lund University have developed a blood test that could offer an earlier and more accurate diagnosis. This would help make sure that people suffering from these diseases are receiving the right kind of treatment sooner.
In order to drive a car, you need a good balance between accelerator and brake. The same applies to a part of the brain – the striatum - that controls our movements. Research at Lund University in Sweden has led to new findings on the interaction between the “accelerator” and the “brake” in the striatum. These findings may guide the development of treatments for movement disorders such as those occurring in Parkinson’s disease.
Laurent Roybon and Oskar Hansson were each awarded research consortia grants from the Norwegian Olav Thon foundation, together with colleagues from other nordic countries.
The Stem Cell Laboratory for CNS Disease Modeling (CSC Laboratory) in Lund, has created one of the largest iPSC biobanks from patients diagnosed with familial and idiopathic PD, and associated synucleionopathies. iPSCs are obtained by reprogramming patient’s somatic cells into pluripotent stem cells.